Jump to content
Paul Edwards

Another new PMSA-linked radioisotope enters clinical trials in prostate cancer

Recommended Posts

Paul Edwards

"Another new form of radioisotope, copper-64 (64Cu), has recently undergone Phase I clinical testing for similar uses when linked to the PSMA-617 ligand.  One of the potential benefits of a 64Cu-PSMA imaging agent is that it is more stable and has a longer half-life than 68Ga.  This means that this imaging agent could be made at a central facility and distributed from there to clinical PET scan centers that don’t have the radiochemistry capabilities necessary for the preparation of 68Ga-PSMA imaging agents."

 

The New Prostate Cancer Infolink has a report on the trial carried out at two nuclear medicine centers (in Vienna, Austria, and Bad Berka, Germany).

 

 

Share this post


Link to post
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.


×
×
  • Create New...